Title: THIOFLAVIN DERIVATIVES FOR USE IN ANTEM DIAGNOSIS OF ALZHEIMER'S DISCOUNTY ON OF AMYLOID DEPOSITION Inventor(s): William E. KLUNK et al. DOCKET NO.: 076333-0281

Thioflavin T (ThT) Proposed Structure of a Major Component of Thioflavin S (ThS)

Figure 1. Structures of a major component of the mixture that comprises Thioflavin S and the chemically well-defined compound, Thioflavin I

Figure 2. Structures of two Thioflavin T analogs in which the quaternary amine of the benzthioazole ring has been replaced with an uncharged tertiary amine.

Title: THIOFLAVIN DERIVATIVES FOR USE IN TANTEMORTEM DIAGNOSI ALZHEIMER'S DISEASE AND IN VIVE GING AND PREVENTION OF AMYLONDEPOSITION Inventor(s): William E. KLUNK et al. DOCKET NO.: 076333-0281

Title: THIOFI AVIN DERIVATIVES FOR USE IN

ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S

DISEASE AND IN VIVO IMAGING AND


PREVENTION OF AMYLOID DEPOSITION

Inventor(s): William E. KLUNK et al.

DOCKET NO.: 076333-0281


Th BT 6-Me-BTA-2


Figure 3. Four serial sections of AD brain frontal cortex stained with the fluorescent dye ThT and three derivatives of ThT are shown. The arrow indicates the same vessel in each section for orientation. Three large amyloid plaques in the mid-lower to right quadrant of each panel are seen clearly with the 6-Me-BTA-0 and 6-Me-BTA-2 stains and are not visualized as well with ThT and BTP stains.



Title: THIOFLAVIN DERIVATIVES FOR USE IN

Right angle view of the left panel, showing ThT and CG binding on CG may bind to Glu-22/Lys-16, while Th7 Figure 4. Proposed sites of Chrysamine G and Thioflavin T binding to a hypothetical β -sheet fibril. ThT and CG may bind to the $A\beta$ fibril on opposite sides. opposite sides of the Aß fibril may bind to Asp-23/His-13.







TITLE: THINFI AVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION Inventor(s): William E. KLUNK et al.

DOCKET NO.: 076333-0281






Figure 6. Time course of radioactivity in the frontal cortex of baboons injected intravenously with 3-5 mCi of ¹¹C-labeled BTA-1, 6-MeO-BTA-1, or 6-Me-BTA-1. Other brain regions, including cerebellum, provided nearly identical time-activity curves indicating a lack of regional uptake preference for the radiotracers in normal brain tissues (see Fig. 7). The smaller inset figure shows the uptake of tracers in the frontal cortex at early time points following injection relative to the blood flow tracer [¹⁵O]water.

TITLE: THIOTLAVIN DERIVATIVES FOR USE IN

The first first than the first the second state of the second sec

TILLE: THOPLAVIN DERIVATIVES FOR USE IN FOR ANTEMORTEM DIAGNOSIS OF ALZHEIMER DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION Inventor(s): William E. KLUNK et al. DOCKET NO.: 076333-0281

Inventor(s): William E. KLUNK et a DOCKET NO.: 076333-0281




Figure 8. Fluorescent micrographs of post-mortem sections from either AD brain or PS1/APP transgenic mouse brain (inset) stained with BTA-1. Left: AD entorhinal cortex showing many NFT in the upper half (two are marked by arrows) and several plaques in the lower half. Right: AD frontal cortex showing several plaques and the cross-section of a blood vessel laden with amyloid (arrowhead). Inset: A single amyloid plaque in the cortex of an 8 month-old PS1/APP mouse. The scale bar represents 100 µm in all micrographs.




Figure 9. Multiphoton microscopic images of amyloid deposits in living PS1/APP mouse brain 24 h after ip injection of 10 mg/kg of BTA-1. These cortical images were obtained using a cortical window preparation slightly lateral to the sagittal suture and just posterior to the coronal suture. The views are projections ~300 μm deep and 615 x 615 μm square. The image on the left reveals several bright plaques in the lower, right portion of the panel and the faint outlines of cerebrovascular amyloid in the upper left portion of the panel. The image on the right shows a distinct amyloid-laden vessel. Note the absence of fluorescence emanating from within the vessels 24 h after the injection of BTA-1. The scale bar is 100 μm.